Reversible ADP Antagonists: New Alternatives To Clopidogrel For Anti-Platelet Therapy In Elective PCI

Reversible ADP Antagonists: New Alternatives To Clopidogrel For Anti-Platelet Therapy In Elective PCI

0:00
24 November 2009

ORLANDO—Deepak Bhatt from the VA Boston Healthcare System and Brigham & Women’s Hospital, talks with Peter Goodwin about findings from the CHAMPION-PLATFORM study (using cangrelor in PCI) a

Deepak Bhatt

Deepak Bhatt

ORLANDO—Deepak Bhatt from the VA Boston Healthcare System and Brigham & Women’s Hospital, talks with Peter Goodwin about findings from the CHAMPION-PLATFORM study (using cangrelor in PCI) and the PLATO study (with ticagrelor in ACS)—testing reversible ADP antagonist agents as anti-platelet therapy, as reported at the American Heart Association Annual Meeting held in Orlando.


LISTEN

[audio:https://www.audiomedica.com/podcasting/cardio/091113DeepakBhattPODCAST.mp3]